Xenothera SAS   Report issue

For profit Phase 2 Phase 3
Founded: Nantes France (2014)

Organization Overview

First Clinical Trial
2019
NCT04431219
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Xenothera SAS

Active Ingredients

Drugs in Phase 3 Trials (1)

xav-19 (2 trials)

Drugs in Phase 2 Trials (4)

methylprednisolone (medrol) (1 trial)

mycophenolate (myfortic) (1 trial)

prednisone (meticorten) (1 trial)

tacrolimus (prograf) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Pneumonia (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 5